Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $61.28MP/E –Yield –
Acrivon Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Acrivon Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $57.40M, down 16.9% year over year. For fiscal 2025 it was $59.99M, down 6.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.99M | -6.3% |
| FY2024 | Dec 31, 2024 | $63.99M | +39.0% |
| FY2023 | Dec 31, 2023 | $46.02M | +92.2% |
| FY2022 | Dec 31, 2022 | $23.95M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.84M | -14.4% |
| Q1 FY2026 | Mar 31, 2026 | $15.17M | -1.6% |
| Q4 FY2025 | Dec 31, 2025 | $14.75M | -20.8% |
| Q3 FY2025 | Sep 30, 2025 | $13.65M | -27.7% |
| Q2 FY2025 | Jun 30, 2025 | $16.18M | +7.7% |
| Q1 FY2025 | Mar 31, 2025 | $15.41M | +34.4% |
| Q4 FY2024 | Dec 31, 2024 | $18.63M | +20.4% |
| Q3 FY2024 | Sep 30, 2024 | $18.86M | +83.7% |
| Q2 FY2024 | Jun 30, 2024 | $15.03M | +42.8% |
| Q1 FY2024 | Mar 31, 2024 | $11.47M | +17.6% |
| Q4 FY2023 | Dec 31, 2023 | $15.48M | – |
| Q3 FY2023 | Sep 30, 2023 | $10.27M | – |
| Q2 FY2023 | Jun 30, 2023 | $10.52M | – |
| Q1 FY2023 | Mar 31, 2023 | $9.76M | – |
See a number that looks wrong?